Continuous hyperfractionated accelerated radiation therapy week-end less in combination with neoadjuvant chemotherapy for the treatment of stage III non-small-cell lung cancer

Lung Cancer

Volumn 60, Issue 1, 2008, Pages 75-82

  Bonomi, Marcelo ^a   Blanco Savorio, Alejandro ^a   Cerchietti, Leandro ^a   Navigante, Alfredo ^a   Castro, Monica ^a   Roth, Berta ^a   Wisnivesky, Juan P ^b  

^a Instituto de Oncologia Angel H Roffo   (Argentina)

^b Division of General Internal Medicine   (United States)

Author keywords

CHARTWEL; Combined chemoradiation; Lung cancer; Radiation therapy; Toxicity; Treatment

Indexed keywords

CISPLATIN; ETOPOSIDE; GEMCITABINE; NAVELBINE; PACLITAXEL;

ADD ON THERAPY; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RADIATION DOSE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; RADIOTHERAPY, CONFORMAL;

EID: 41149124091     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.09.003     Document Type: Article

References (34)

1. Perez C.A., Pajak T.F., Rubin P., et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer 59 (1987) 1874-1881
2. Payne D.G. Non-small-cell lung cancer: should unresectable stage III patients routinely receive high-dose radiation therapy?. J Clin Oncol 6 (1988) 552-558
3. Sause W., Kolesar P., Taylor S.I., et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117 (2000) 358-364
4. Dillman R.O., Seagren S.L., Propert K.J., et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323 (1990) 940-945
5. Le Chevalier T., Arriagada R., Quoix E., et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83 (1991) 417-423
6. Saunders M.I., Bennett M.H., Dische S., et al. Primary tumor control after radiotherapy for carcinoma of the bronchus. Int J Radiat Oncol Biol Phys 10 (1984) 499-501
7. Cox J.D. Induction chemotherapy for non-small cell carcinoma of the lung: limitations and lessons. Int J Radiat Oncol Biol Phys 20 (1991) 1375-1376
8. Saunders M.I., and Dische S. Continuous, hyperfractionated, accelerated radiotherapy (CHART) in non-small cell carcinoma of the bronchus. Int J Radiat Oncol Biol Phys 19 (1990) 1211-1215
9. Saunders M., Dische S., Barrett A., et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet 350 (1997) 161-165
10. Saunders M., Dische S., Barrett A., et al. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. Radiother Oncol 52 (1999) 137-148
11. Saunders M.I., Rojas A., Lyn B.E., et al. Experience with dose escalation using CHARTWEL (continuous hyperfractionated accelerated radiotherapy weekend less) in non-small-cell lung cancer. Br J Cancer 78 (1998) 1323-1328
12. Rojas A.M., Lyn B.E., Wilson E.M., et al. Toxicity and outcome of a phase II trial of taxane-based neoadjuvant chemotherapy and 3-dimensional, conformal, accelerated radiotherapy in locally advanced nonsmall cell lung cancer. Cancer 107 (2006) 1321-1330
13. Armstrong J.G., Burman C., Leibel S., et al. Three-dimensional conformal radiation therapy may improve the therapeutic ratio of high dose radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys 26 (1993) 685-689
14. Hayman J.A., Martel M.K., Ten Haken R.K., et al. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. J Clin Oncol 19 (2001) 127-136
15. Rosenzweig K.E., Sim S.E., Mychalczak B., et al. Elective nodal irradiation in the treatment of non-small-cell lung cancer with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 50 (2001) 681-685
16. McGibney C., Holmberg O., McClean B., et al. Dose escalation of chart in non-small cell lung cancer: is three-dimensional conformal radiation therapy really necessary?. Int J Radiat Oncol Biol Phys 45 (1999) 339-350
17. ICRU Report 50: Prescribing, Recording and Reporting Photon Beam Therapy. International Commission on Radiation Units and Measurements. Bethesda, MD.
18. Armstrong J., Raben A., Zelefsky M., et al. Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer. Radiother Oncol 44 (1997) 17-22
19. Graham M.V., Matthews J.W., Harms Sr. W.B., et al. Three-dimensional radiation treatment planning study for patients with carcinoma of the lung. Int J Radiat Oncol Biol Phys 29 (1994) 1105-1117
20. Mehta M.P., Tannehill S.P., Adak S., et al. Phase II trial of hyperfractionated accelerated radiation therapy for nonresectable non-small-cell lung cancer: results of Eastern Cooperative Oncology Group 4593. J Clin Oncol 16 (1998) 3518-3523
21. Green M.R., Ginsberg R., Ardizzoni A., et al. Induction therapy for stage III NSCLC: a consensus report. Lung Cancer 11 Suppl 3 (1994) S9-S10
22. Cancer Therapy Evaluation Program 35 Revised March 23, 1998. Common Toxicity Criteria, Version 2.0. DCTD, NCI, NIH, DHHS March 1998. http://ctep.cancer.gov/forms/CTCv20_4-30-992.pdf.
23. Kaplan E., and Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 53 (1958) 457-481
24. Collet D. Modelling Survival Data in Medical Research (1994), CRC Press, New York, NY
25. Dillman R.O., Herndon J., Seagren S.L., et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 88 (1996) 1210-1215
26. Zatloukal P., Petruzelka L., Zemanova M., et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 46 (2004) 87-98
27. Curran WJ, Scott CB, Langer CJ, et al. Long-term benefit is observed in a phase III comparison of sequential vs. concurrent chemoradiation for patients with unresected stage III NSCLC: RTOG 9410. Abstract 2499; Proc ASCO 22:621,2003.
28. Perez C.A., Stanley K., Rubin P., et al. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group. Cancer 45 (1980) 2744-2753
29. Kong F.M., Ten Haken R.K., Schipper M.J., et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys 63 (2005) 324-333
30. Sorensen P., and Hansen O. The location of recurrencies in patients with non-small cell lung cancer treated with involved-field irradiation. Lung Cancer 29 (2000) S171
31. Belderbos J.S., De Jaeger K., Heemsbergen W.D., et al. Interim analysis of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy. IJROBP 51 (2001) S2232
32. Kirkbride P., Hatton M., Lorigan P., et al. Fatal pulmonary fibrosis associated with induction chemotherapy with carboplatin and vinorelbine followed by CHART radiotherapy for locally advanced non-small cell lung cancer. Clin Oncol (R Coll Radiol) 14 (2002) 361-366
33. Belani C.P., Wang W., Johnson D.H., et al. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. J Clin Oncol 23 (2005) 3760-3767
34. Ishikura S., Ohe Y., Nihei K., et al. A phase II study of hyperfractionated accelerated radiotherapy (HART) after induction cisplatin (CDDP) and vinorelbine (VNR) for stage III non-small-cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 61 (2005) 1117-1122